84596-08-7

Usage

Uses

Used in Pharmaceutical Industry:
2-Pyridinamine, 5-(4-chlorophenyl)is used as a synthetic intermediate for the development of various pharmaceuticals. Its unique structure allows it to be incorporated into the design of new drugs, potentially leading to the discovery of novel therapeutic agents with improved efficacy and selectivity.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Pyridinamine, 5-(4-chlorophenyl)is employed as a precursor in the synthesis of agrochemicals, such as pesticides and herbicides. Its incorporation into these compounds can enhance their effectiveness in controlling pests and weeds, thereby contributing to increased crop yields and agricultural productivity.
Used in Organic Chemistry:
2-Pyridinamine, 5-(4-chlorophenyl)serves as a building block in organic chemistry, enabling the synthesis of a wide range of organic compounds. Its versatile structure can be further modified through various chemical reactions, allowing for the creation of new molecules with diverse applications in fields such as materials science, catalysis, and medicinal chemistry.

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 1679-18-1 4-Chlorophenylboronic acid 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 274251-56-8 boronic acid 4-chlorophenyl monoester 

Downstream Products

• 84596-52-1 5-(4-chlorophenyl)-2-pyridylamine-1-oxide 
• 690264-18-7 5-(4-chloro-phenyl)-2-iodo-pyridine 
• 1044239-23-7 N-[5-(4-chlorophenyl)pyridin-2-yl]benzamide 
• 918516-27-5 5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine 
• 1029872-54-5 vemurafenib 
• 911113-60-5 C₁₁H₈BrClN₂ 
• 1356397-47-1 C₁₅H₁₅ClN₂O 
• 1356397-48-2 5-(4-Cl-phenyl)azaindole 
• 1356397-46-0 C₁₁H₈ClIN₂ 

Relevant academic research and scientific papers

Imidazo[1,2- a]pyridine derivatives as aldehyde dehydrogenase inhibitors: Novel chemotypes to target glioblastoma stem cells

Glioblastoma multiforme (GBM) is the deadliest form of brain tumor. It is known for its ability to escape the therapeutic options available to date thanks to the presence of a subset of cells endowed with stem-like properties and ability to resist to cyto

Novel Processes for the manufacture of Propane-1-sulfonic acid -amide

According to the present invention there are provided novel processes for the manufacture of the compound of formula 1 as well as intermediates and novel synthesis routes for key intermediates used in those processes.

NOVEL PROCESSES FOR THE MANUFACTURE OF PROPANE-1-SULFONIC ACID {3-[5-(4-CHLORO-PHENYL)-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL]-2,4-DIFLUORO-PHENYL}-AMIDE

According to the present invention there are provided novel processes for the manufacture of the compound of formula (1) as well as novel synthesis routes for key intermediates used in those processes.

False positives in a reporter gene assay: Identification and synthesis of substituted N-pyridin-2-ylbenzamides as competitive inhibitors of firefly luciferase

Luciferase reporter-gene assays are a commonly used technique in high-throughput screening campaigns. In this study, we report on a luciferase inhibitor (1), which emerged from an antagonistic G protein-coupled receptor luciferase reporter-gene assay scre

Novel compounds as metabotropic glutamate receptor antagonists

The present invention relates to compounds of formula (I) wherein A, E G, J, L, M, R1, R2, and R3 are as defined in the specification and claims. The invention also relates to pharmaceutical compositions containing such compounds and methods for preparing the compounds and compositions. The compounds are metabotropic glutamate receptor antagonists and are useful for the treatment of a variety of CNS disorders.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to alkyne compounds of general formula I wherein the groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS

The invention relates to alkyne compounds of general formula (I), in which groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings as cited in Claim 1. The invention also relates to medicaments containing at least one inventive alkyne. The MCH receptor antagonistic effect renders the inventive medicaments suitable for treating metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia and diabetes.

1-Benzoyl-3-(arylphyridyl)urea compounds

The present invention is directed to 1-benzoyl-3-(arylpyridyl)urea compounds useful as insecticides.